v2.3.0.11
Business Segments and Geographic Information
9 Months Ended
Jun. 25, 2011
Business Segments and Geographic Information  
Business Segments and Geographic Information

(12) Business Segments and Geographic Information

The Company reports segment information in accordance with ASC 280, Segment Reporting. Operating segments are identified as components of an enterprise for which separate, discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The Company's chief operating decision maker is its chief executive officer, and the Company's reportable segments have been identified based on the types of products manufactured and the end markets to which the product are sold into. Each reportable segment generates revenue from either the sale of medical equipment and related services and/or the sale of disposable supplies, primarily used for diagnostic testing and surgical procedures. The Company has four reportable segments: Breast Health, Diagnostics, GYN Surgical and Skeletal Health. Certain reportable segments represent an aggregation of operating units within each segment. The Company measures and evaluates its reportable segments based on segment revenues and operating income.

Identifiable assets for the four principal operating segments consist of inventories, intangible assets, and property and equipment. The Company fully allocates depreciation expense to its four reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no intersegment revenues during the three and nine months ended June 25, 2011 and June 26, 2010.

Segment information is as follows:

     Three Months Ended      Nine Months Ended  
     June 25,
2011
    June 26,
2010
     June 25,
2011
     June 26,
2010
 

Total revenues:

          

Breast Health

   $ 205,185      $ 189,361       $ 606,403       $ 557,891   

Diagnostics

     143,446        137,378         420,777         417,755   

GYN Surgical

     79,353        71,567         226,526         210,158   

Skeletal Health

     23,098        22,387         68,598         65,449   
                                  
   $ 451,082      $ 420,693       $ 1,322,304       $ 1,251,253   
                                  

Operating income (loss):

          

Breast Health

   $ 47,230      $ 37,505       $ 132,365       $ 85,793   

Diagnostics

     24,052        25,759         157,149         78,784   

GYN Surgical

     (483     12,829         2,660         41,044   

Skeletal Health

     3,117        2,681         8,850         7,023   
                                  
   $ 73,916      $ 78,774       $ 301,024       $ 212,644   
                                  

Depreciation and amortization:

          

Breast Health

   $ 10,366      $ 12,682       $ 30,344       $ 37,975   

Diagnostics

     40,452        41,661         120,218         124,309   

GYN Surgical

     23,474        17,154         66,994         51,288   

Skeletal Health

     2,861        3,039         8,802         8,753   
                                  
   $ 77,153      $ 74,536       $ 226,358       $ 222,325   
                                  

Capital expenditures:

          

Breast Health

   $ 1,815      $ 2,734       $ 9,592       $ 7,832   

Diagnostics

     6,433        4,540         17,906         12,746   

GYN Surgical

     3,419        1,797         8,302         7,108   

Skeletal Health

     1,083        873         2,133         3,094   

Corporate

     2,098        1,774         4,602         3,567   
                                  
   $ 14,848      $ 11,718       $ 42,535       $ 34,347   
                                  

 

     June 25,
2011
     September 25,
2010
 

Identifiable assets:

     

Breast Health

   $ 998,151       $ 988,041   

Diagnostics

     1,795,962         1,802,148   

GYN Surgical

     2,072,064         1,834,773   

Skeletal Health

     31,940         30,293   

Corporate

     1,039,106         970,579   
                 
   $ 5,937,223       $ 5,625,834   
                 

The Company had no customers with balances greater than 10% of accounts receivable as of June 25, 2011 or September 25, 2010, or any customer that represented greater than 10% of product revenues during the three and nine months ended June 25, 2011 and June 26, 2010.

The Company operates in the major geographic areas as noted in the below chart. Product sales data is based upon customer location, and internationally totaled $91.4 million and $261.2 million during the three and nine months ended June 25, 2011, respectively, and $75.2 million and $228.4 million during the three and nine months ended June 26, 2010, respectively. The Company's sales in Europe are predominantly derived from Germany, the United Kingdom and the Netherlands. The Company's sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The "All others" designation includes Canada, Latin America and the Middle East. Products sold by the Company internationally are manufactured at both domestic and international locations.

Product sales by geography as a percentage of total product sales are as follows:

   Three Months Ended     Nine Months Ended  
     June 25,
2011
    June 26,
2010
    June 25,
2011
    June 26,
2010
 

United States

     75     79     76     77

Europe

     15     12     14     12

Asia-Pacific

     6     5     6     6

All others

     4     4     4     5
  

 

 

   

 

 

   

 

 

   

 

 

 
     100     100     100     100